Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

2026年6月2日，全球支付技术公司Visa宣布完成对云端编程平台Repl.it的战略投资。此次投资旨在加强双方在技术领域的合作，推动在线编程教育与创新应用的发展。 Repl.it是美国一家基于云端的程序语言在线交互式平台，用户可以直接在浏览器上学习和体验各种编程 ...

REPL shares soared 85.7% after FDA alignment on RP1 plus Opdivo BLA resubmission plans. Replimune plans to resubmit the BLA in the coming days. The FDA intends to prioritize review. The RP1 plus ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Replimune Group, Inc.'s RP1 has failed at the FDA twice, but Makary's resignation keeps a resubmission possible. REPL's cash runway stands at under a year; workforce cuts and RP1 discontinuation are ...

This project is a proof-of-concept that runs a JavaScript engine inside a web browser by compiling it to WebAssembly. The engine is Goja — a pure-Go implementation of ECMAScript 5.1 — and the ...

FDA has now rejected Replimune’s melanoma immunotherapy RP1 on two separate occasions The drug was under consideration for use with Bristol Myers Squibb’s (BMY) Opdivo therapy Regulators maintained ...

During the previous two years, 175 institutional investors and hedge funds held shares of Replimune Group. The most heavily invested institutionals were Baker BROS. Advisors LP ($121.06M), Price T ...

Shares of Replimune Group, Inc. (REPL Quick Quote REPL - Free Report) have gained 2.7% over the past four weeks to close the last trading session at $7.16, but there could still be a solid upside left ...